Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 11Other hematologic neoplasm 3Sarcoma 2Plasma cell 2Head & Neck 2Gastrointestinal 2Dermatologic 2CNS 2Breast 2Thoracic 1Genitourinary 1

Conditions

Squamous Cell Carcinoma of Head and Neck 18Head and Neck Neoplasms 10Melanoma 9Carcinoma, Non-Small-Cell Lung 7Triple Negative Breast Neoplasms 6Carcinoma, Transitional Cell 6Uterine Cervical Neoplasms 5Stomach Neoplasms 5Colorectal Neoplasms 5Carcinoma, Renal Cell 5Carcinoma, Hepatocellular 5Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Nasopharyngeal Carcinoma 4Carcinoma, Merkel Cell 4Thyroid Neoplasms 3Sarcoma 3Salivary Gland Neoplasms 3Endometrial Neoplasms 3Urinary Bladder Neoplasms 2Recurrence 2Prostatic Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Mesothelioma 2Lymphoma 2Liver Neoplasms 2Histiocytoma, Malignant Fibrous 2Esophageal Neoplasms 2

Interventions

pembrolizumab 9Nivolumab 5epacadostat 2Thiotepa 2Nonlinear Optical Microscopy 2Magnetic Resonance Spectroscopy 2Magnetic Resonance Imaging 2Ipilimumab 2Filgrastim 2Cytological Techniques 2Cyclophosphamide 2Biopsy, Fine-Needle 2Biopsy 2vocimagene amiretrorepvec 1ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1spartalizumab 1sapanisertib 1romidepsin 1relatlimab 1poly ICLC 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1motexafin gadolinium 1larotrectinib 1ipatasertib 1fludarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma × Ipilimumab × Head & Neck × Clear all
NCT03058289 2025-02-27

IT-01

Intensity Therapeutics, Inc.

Phase 1/2 Completed
111 enrolled 21 charts
BreastGastrointestinalHead & NeckLymphoidSarcomaThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Squamous Cell, Colonic Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms, Sarcoma

NCT01986426 2018-10-03

LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab

Lytix Biopharma AS

Phase 1 Completed
80 enrolled
BreastDermatologicHead & NeckLymphoid

Breast Neoplasms, Head and Neck Neoplasms, Lymphoma, Melanoma, Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡